How Henry R. Luce and Clare Boothe Luce helped turn America on to LSD + Some Notes

The Time and Life Acid Trip: How Henry R. Luce and Clare Boothe Luce helped turn America on to LSD. (archived)

I accidentally came across this when I was looking into Henry Luce, some more. It doesn’t mention Luce’s ties to the CIA, i.e. Operation Mockingbird. The notes are from another project that I’ve been slowly working on. That one I won’t be publicizing until I’m finished with it.

Related & Notes:

Stephen Siff: Henry Luce’s Strange Trip: Coverage of LSD in Time and Life, 1954-68

Read More »

A brief, weird history of brainwashing

On an early spring day in 1959, Edward Hunter testified before a US Senate subcommittee investigating “the effect of Red China Communes on the United States.” It was the kind of opportunity he relished. A war correspondent who had spent considerable time in Asia, Hunter had achieved brief media stardom in 1951 after his book Brain-Washing in Red China introduced a new concept to the American public: a supposedly scientific system for changing people’s minds, even making them love things they once hated.

But Hunter wasn’t just a reporter, objectively chronicling conditions in China. As he told the assembled senators, he was also an anticommunist activist who served as a propagandist for the OSS, or Office of Strategic Services — something that was considered normal and patriotic at the time. His reporting blurred the line between fact and political mythology.

A brief, weird history of brainwashing

Related:

Read More »

Israeli Group to Study MDMA Therapy for October 7 Survivors With PTSD

Israeli Group to Study MDMA Therapy for October 7 Survivors With PTSD

A group of 400 Israeli survivors of the October 7 Hamas attack, including civilians, released hostages, and soldiers, could be offered MDMA-assisted psychotherapy in a potentially trailblazing study to commence later this year.

“Our goal is to create a therapy model that can serve universally, with the intention and prayer to help people,” said Dr. Keren Tzarfaty, CEO and co-founder of MAPS Israel, which is already running trials evaluating MDMA-assisted therapy for the treatment of post-traumatic stress disorder, depression, and eating disorders. “We hope it will demonstrate high levels of safety and effectiveness and enable us to offer the program in other places over the region and the world, not only to treat PTSD, but to help people open their hearts and expand their minds.”

Dr. Rick Doblin, founding president of the U.S.-based MAPS and a longtime advocate for using psychedelic therapy in the Israeli–Palestinian conflict, said that the study would serve as a seminal piece of research into whether psychedelic-assisted therapy can help large groups of traumatized people.

Read More »

Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here’s What’s Next

Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here’s What’s Next

Yet one glaring problem remains. Despite promising clinical results, no one knows exactly how psychedelic drugs work in the brain. Examining their actions on brain cells isn’t just an academic curiosity. It could give rise to variants that maintain antidepressant properties without the high. And because hallucinogens substantially alter our perception [management?!] of the world, they could be powerful tools for investigating the neurobiology behind consciousness.

This year, scientists found another common themepsychedelics seem to “reset” the brain to a more youthful state, at least in mice. Like humans, mice have an adolescent critical period, during which their brains are highly malleable and can easily rewire neural circuits, but the window closes after adulthood.

An earlier study showed that MDMA reopens the critical window in adult mice, so that they change their “personality.” Mice raised alone are often introverted and prefer to keep to themselves in adulthood. A dose of MDMA increased their willingness to snuggle with other mice—essentially, they learned to associate socializing with happiness, concluded the study.

It’s not that surprising. MDMA is well-known to promote empathy and bonding. The new study, by the same team, extended their early results to four psychedelics that don’t trigger fuzzy feelings—LSD, ketamine, psilocybin, and ibogaine. Similar to MDMA, adult mice raised alone changed their usual preference for solitude when treated with any of the drugs. Because habits are hard to change in adulthood—for mice and men—the drugs may have reopened the critical period, allowing the brain to more easily rewire neural connections based on new experiences.

These are just early results. But psychedelic research is gaining a new ally—artificial intelligence. Algorithms that predict protein structure, combined with rational drug design, could generate psychedelics that retain their psychiatric benefits without the high.

H/T: The Most Revolutionary Act

Related:

Psychoanalytic roots of CIA psychoprofiling/pseudoscience

Meaghan thought psychedelic therapy could help her PTSD. Instead it was the start of a nightmare

Why is the American right suddenly so interested in psychedelic drugs

What if a Pill Can Change Your Politics or Religious Beliefs? (archived)

Do Psychedelic Trips Change Your Political Views? (archived)

Dan Crenshaw’s measure greenlighting psychedelics to treat PTSD part of defense bill + More

The legislation would allow supervised clinical studies with active-duty members.

Dan Crenshaw’s measure greenlighting psychedelics to treat PTSD part of defense bill

Related:

First-ever provision for psychedelic studies included in defense bill

National Defense Authorization Act, pp. 402-406, p. 1817 ($50,311 allocated for R&D)

CIA MKULTRA / Mind Control Collection

FDA Weighs New Application To Approve MDMA As First-Ever Psychedelic Medicine For PTSD + More About MAPS

FDA Weighs New Application To Approve MDMA As First-Ever Psychedelic Medicine For PTSD + More About MAPS

A psychedelics-focused drug development company is officially asking the Food and Drug Administration (FDA) to review an application to approve MDMA as a prescription medication for the treatment of post-traumatic stress disorder (PTSD).

The MAPS Public Benefit Corporation (MAPS PBC) announced on Tuesday that it submitted the new drug application (NDA) to FDA, requesting an expedited review given that the agency previously designated the psychedelic as a breakthrough therapy.

FDA Weighs New Application To Approve MDMA As First-Ever Psychedelic Medicine For PTSD

H/T: The Most Revolutionary Act

The MAPS Public Benefit Corporation is subsidiary of Multidisciplinary Association for Psychedelic Studies. MAPS was founded by Rick Doblin.*

Related:

Read More »

How the CIA Illegally Used African Americans for Experimental Drug Research

By now, many will be familiar with Project MKULTRA. For decades, the CIA conducted highly unethical experiments on humans in order to perfect brainwashing, mind control and torture techniques.

Perhaps the program’s most notorious aspect was the administration of high doses of psychoactive drugs to targets, particularly LSD. These substances were brought to Langley’s attention in 1948 by Richard Kuhn, one of 1,600 Nazi scientists covertly spirited to the U.S. via Operation Paperclip following World War II. When MKULTRA was formally established five years later, some individuals consulted directly on the project.

How the CIA Illegally Used African Americans for Experimental Drug Research